Finance

Beta
Lists
CADL:NASDAQ
Candel Therapeutics Inc
$10.30
-0.58%
(-0.060) 1D
$10.25
-0.49% (-0.050)
After hours
Closed: Jun 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for CADL...
Open
$10.44
High
$11.36
Low
$10.27
Mkt. cap
754.68M
Avg. vol.
2.16M
Volume
2.94M
52-wk high
$11.36
52-wk low
$4.35
EPS
-$0.98
Beta
-0.49
Shares outstanding
73.27M
No. of employees
55
Open
$10.44
High
$11.36
Low
$10.27
Mkt. cap
754.68M
Avg. vol.
2.16M
Volume
2.94M
52-wk high
$11.36
52-wk low
$4.35
EPS
-$0.98
Beta
-0.49
Shares outstanding
73.27M
No. of employees
55
News stories
From sources across the web
About Candel Therapeutics Inc
CEO-
Employees55
Founded2003
HeadquartersNeedham, Massachusetts, United States
SectorBiotechnology
Websitecandeltx.com
Analyst ratings
Based on 5 analysts giving stock ratings to CADL in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for CADL in the last 3 months.
Highest
Current $10.30
$30.00 (+191.26%)
Average
$20.60 (+100.00%)
Lowest
$9.00 (-12.62%)
Analyst
Recommendation
Action
Price target
Projected
Date
Andres Y. Maldonado
H.C. Wainwright
Buy
Maintained
$23.00
+123.3%
06/02/2026
Alec Stranahan
Bank of America Securities
Hold
Maintained
$9.00
-12.6%
05/31/2026
John Newman
Canaccord Genuity
Buy
Maintained
$25.00
+142.7%
05/18/2026
Oliver McCammon
LifeSci Capital
Buy
Reiterated
$16.00
+55.3%
05/16/2026
Unknown Analyst
Cantor Fitzgerald
Buy
Initiated
$30.00
+191.3%
04/20/2026
Yigal Nochomovitz
Citi
Buy
Reiterated
$26.00
+152.4%
03/18/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
6.84M
8.31M
10.82M
9.64M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4.34M
4.90M
4.93M
6.64M
Operating expense
11.18M
13.21M
15.74M
16.28M
Total operating expenses
11.18M
13.21M
15.74M
16.28M
Operating income
-11.18M
-13.21M
-15.74M
-16.28M
Other non operating income
5.69M
1.15M
-13.43M
7.66M
EBT including unusual items
-4.80M
-11.27M
-29.50M
-8.86M
EBT excluding unusual items
-4.80M
-11.27M
-29.49M
-8.86M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-4.80M
-11.27M
-29.50M
-8.86M
Net profit margin
-
-
-
-
Earnings per share
-0.20
-0.23
-0.29
-
Interest and investment income
926.00K
953.00K
1.10M
1.32M
Interest expense
-236.00K
-161.00K
-1.42M
-1.56M
Net interest expenses
690.00K
792.00K
-314.00K
-242.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-10.94M
-13.01M
-15.58M
-16.14M
Gain or loss from assets sale
11.00K
328.00K
-33.00K
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer